Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
Serina Therapeutics, Inc.(US:SER) Globenewswire·2025-07-29 18:44- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington's chorea – an underserved indication with high need for long-acting VMAT2 therapy - HUNTSVILLE, AL, July 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, today announced the advancement of its novel prod ...